|
Patent landscape, scope, and claims: |
US Patent 8,088,934 Scope and Claims: What Is Claimed, What Is Not, and How the Patent Estate Carries Risk
United States Patent 8,088,934 claims two closely related stereochemically defined bicyclic oxabicyclo[4.3.0]nonane carboxylic acid compounds (and salts/esters/amides/ethers), each specified as being present as a substantially pure bicyclic (100:0) relative to a “tautomeric monocyclic” compound. The patent’s practical reach is narrow: it is claim-structure centric (exact formula + stereochemistry) and purity/tautomer ratio centric (100:0), leaving limited room for generic design-arounds that change substitution, stereochemistry, or tautomer composition.
What does US 8,088,934 claim: bicyclic oxabicyclo[4.3.0]nonane compounds with a 100:0 tautomer ratio?
Claim set (1–4) is directed to a pair of bicyclic compounds defined by (i) a precise heptanoic-acid substitution pattern on the bicyclic core and (ii) one of two difluoroalkyl side chains with fixed stereochemistry, plus (iii) an explicit tautomeric purity constraint requiring the bicyclic species to exist in substantially 100:0 ratio versus a “tautomeric monocyclic compound.”
Claim 1 (core scope)
- Bicyclic formula: 7-[(1R,3R,6R,7R)-3-(1,1-difluoropentyl)-3-hydroxy-2-oxabicyclo[4.3.0]nonane-8-one-7-yl]heptanoic acid
- Claim coverage includes salts, ethers, esters, and amides of the above compound.
- Key limitation: the bicyclic compound is present in a substantially 100:0 ratio relative to its tautomeric monocyclic compound.
Claim 2 (alternative stereochemical side-chain)
- Bicyclic formula: 7-[(1R,6R,7R)-3-[(3S)-1,1-difluoro-3-methylpentyl]-3-hydroxy-2-oxabicyclo[4.3.0]nonane-8-one-7-yl]heptanoic acid
- Includes salts, ethers, esters, amides of the compound.
- Same purity limitation: substantially 100:0 bicyclic vs tautomeric monocyclic.
Claims 3 and 4 (species narrowing)
- Claim 3 narrows Claim 1 to the exact compound (same as the Claim 1 bicyclic structure without further variants).
- Claim 4 narrows Claim 2 to the exact compound (same as Claim 2 bicyclic structure).
Practical point: Claims 3 and 4 are species claims that track the exact formula recited in Claims 1 and 2, so the enforceable coverage is largely determined by how courts interpret:
- the meaning of “tautomeric monocyclic compound,”
- the measurement and proof requirements for “substantially 100:0,” and
- whether salts/esters/amides/ethers “read on” downstream compositions that differ in hydrolysis state, ester interchange, or formulation equilibrium.
How broad are the “salt, ether, ester, or amide” provisions in US 8,088,934?
The claim language is drafted as a derivatives rider: it covers the bicyclic parent plus salts and functional-group derivatives (ether, ester, amide).
Coverage triggers
- If the “bicyclic compound” is present as the defined species (tautomer ratio limitation still applies), then:
- A carboxylate salt (e.g., with an inorganic or organic base) is typically inside scope.
- An ester or amide of the heptanoic acid function or a corresponding functional group is typically inside scope, depending on how the claim construction identifies the reactive position(s) in the bicyclic compound.
- An ether suggests there is an alcohol handle that can be etherified, which is consistent with the explicit 3-hydroxy in the bicyclic core.
Key boundary
The claim does not say “pharmaceutically acceptable.” It says “or a salt, ether, ester or amide thereof.” That can broaden the theoretical set of derivatives, but enforceability still depends on:
- whether the derivative remains the same bicyclic compound identity for tautomer counting; and
- whether the derivative alters tautomer equilibrium away from “substantially 100:0.”
What exactly is the “tautomeric monocyclic compound” and how does the 100:0 ratio limit enforceability?
The most litigation-relevant phrase in these claims is:
- “the bi-cyclic compound is present in a ratio of substantially 100:0 with respect to its tautomeric monocyclic compound.”
Litigation-grade construction issues
-
Identity of the monocyclic tautomer
The claim assumes there is a specific tautomeric monocyclic form corresponding to the bicyclic species. Patent infringement typically turns on whether accused products contain that tautomer and whether it can be detected and quantified.
-
Measurement method
“Substantially 100:0” is quantitative but not defined by method. Typical proof disputes include:
- chromatographic separation capability,
- whether tautomerization occurs during sample prep,
- whether equilibrium composition is stabilized by excipients, salts, or polymorphs, and
- whether analysis targets the free acid form or salt/ester forms.
-
Time dependence and storage condition
If bicyclic-to-monocyclic interconversion occurs, the accused product might satisfy “100:0” at one timepoint and not another. Claim language does not state “at administration” or “at isolation,” which can increase factual disputes.
-
Formulation equilibrium
For derivatives (salts/esters/amides/ethers), the functional group conversion can shift tautomer balance. The claim’s tautomer constraint can therefore make “formulation design” an IP barrier, even when the structure otherwise matches.
Enforceable reading
- The claim is not merely structural. It requires a composition state: essentially no monocyclic tautomer.
- That makes the scope narrower than a purely Markush-style “compound of formula” claim without purity limitations.
What chemical changes avoid infringement: stereochemistry, difluoroalkyl substitution, and oxabicyclo core?
Given the explicit stereochemical descriptors and side-chain patterning, design-around risk is highest for competitors that change any of the following:
1) Stereochemistry at the bicyclic core
- Claim 1 requires (1R,3R,6R,7R).
- Claim 2 requires a reduced set of stereocenters in the descriptor (1R,6R,7R) plus a defined chiral center on the side chain (3S).
- Changing absolute configuration is the most direct structural noninfringement route, assuming the stereocenters map cleanly onto the bicyclic framework and that stereochemical descriptors are treated as claim limitations.
2) Side-chain identity (difluoroalkyl substitution)
- Claim 1: 1,1-difluoropentyl.
- Claim 2: 1,1-difluoro-3-methylpentyl (with chiral carbon (3S)).
Changing:
- the carbon count,
- the branching pattern (methyl placement),
- or the difluoro substitution pattern,
should avoid the exact formula language.
3) Tautomer ratio (100:0)
Even with the correct structure, a competitor could attempt to design a product with measurable monocyclic tautomer presence, breaking “substantially 100:0.” In practice, this can be difficult because equilibria may shift during manufacturing or storage, and regulators may drive purity specs toward low impurity including tautomer content. Still, it is a claim-specific lever.
How strong is the patent estate position of US 8,088,934 without dependents or family context?
Based only on the claim text provided, the patent has the following strength characteristics:
Strength characteristics
- Definite chemical identity: fixed formula and defined stereochemistry reduce ambiguity.
- Additional composition limitation: “substantially 100:0” adds another potential barrier.
- Two distinct chemical species: Claim 1 and Claim 2 cover two different difluoroalkyl substitution variants.
Weakness characteristics
- Narrow formula space: only two species patterns are claimed (plus derivatives).
- High proof burden: infringement requires demonstrating the tautomer ratio and identifying the monocyclic tautomer.
- Potential reliance on claim construction: “tautomeric monocyclic compound” and “substantially” invite expert disputes.
Without the rest of the patent file history, priority claims, prosecution amendments, specification detail, and the broader family landscape, the enforceability of the “tautomeric monocyclic” limitation and the breadth of derivatives cannot be scored against the likely prior art.
How many infringement pathways exist: structural match vs tautomer-ratio compliance?
A practical infringement assessment separates two gates:
Gate A: Structure match
- Does the accused compound contain the oxabicyclo[4.3.0]nonane core with the specified heptanoic acid linkage and hydroxyl at the 3-position?
- Does it have the correct difluoroalkyl side chain (1,1-difluoropentyl or 1,1-difluoro-3-methylpentyl)?
- Does it have the correct absolute configuration?
Gate B: Composition match
- Is the bicyclic species present at substantially 100:0 relative to its monocyclic tautomer?
A generic or follow-on that fails Gate A is outside claim scope even if purity is high. A formulation that fails Gate B could be outside scope even if structure matches.
Does US 8,088,934 cover prodrugs, salts used in formulations, and ester prodrugs?
The derivatives rider suggests it can cover certain prodrug-like transformations, but infringement hinges on:
- whether the derivative keeps the bicyclic identity and
- whether the derivative changes tautomeric distribution.
Common risk points
- Ester hydrolysis on dosing can convert the administered form into the parent acid. If conversion changes the tautomer equilibrium, infringement may become multi-stage and depend on when the “ratio” is measured.
- Salt selection can change equilibrium and stability, which affects whether “substantially 100:0” holds at manufacturing release, storage, or administration.
What patent landscape questions should be answered next for a full freedom-to-operate?
A complete US FTO typically requires mapping:
- whether there are continuations or family members with broader Markush ranges,
- whether there are process patents that cover synthesis of the bicyclic compound,
- whether there are formulation or polymorph patents that control tautomer equilibrium,
- whether the patent is tied to a specific active ingredient name in FDA submissions.
However, the request is limited to the scope and claims of US 8,088,934 as provided. Without the rest of the record (title, assignee, priority, specification disclosure, cited art, and FDA/Orange Book mapping), the landscape cannot be constructed to a litigation-usable standard.
Key Takeaways
- US 8,088,934 claims two tightly defined bicyclic oxabicyclo[4.3.0]nonane heptanoic acids with fixed absolute stereochemistry and difluoroalkyl side chains.
- The patent’s decisive limitation is not only structure but also a composition requirement: the bicyclic compound must be present at substantially 100:0 versus a tautomeric monocyclic compound.
- The “salt, ether, ester, or amide” language extends coverage to derivatives, but infringement still requires the tautomer ratio constraint to be satisfied.
- Design-arounds have the strongest leverage via stereochemistry change, side-chain substitution change, or ensuring detectable monocyclic tautomer presence that breaks the “100:0” requirement.
- The enforceability profile is narrow but proof-intensive, making factual analysis of tautomer identity and quantification central to any infringement or validity fight.
FAQs
-
Can a competitor infringe US 8,088,934 with the same bicyclic structure but with nonzero monocyclic tautomer content?
Under the claim language, infringement requires “substantially 100:0,” so detectable monocyclic tautomer content can be a noninfringement lever if it is sufficiently high to defeat the “substantially” threshold.
-
Do salts or ester prodrugs avoid infringement if tautomer equilibrium shifts in the solid state or during storage?
The derivatives are covered only “thereof” the bicyclic compound, and the tautomer ratio limitation still applies. Shifting equilibrium can affect whether the claim’s “100:0” condition is met at the relevant time.
-
Is the claim limited to “free acid” only, or does it cover carboxylate salts and related esters/amides?
The claim expressly includes “salt, ether, ester or amide” of the bicyclic compound, which extends beyond the free acid form.
-
Which change is most likely to avoid infringement: stereochemistry, side chain branching, or tautomer control?
Structural changes to stereochemistry or side-chain identity avoid the formula language. Tautomer control can also avoid infringement but is analytically and evidentially complex.
-
Do claims 3 and 4 add meaningful scope beyond claims 1 and 2?
Claims 3 and 4 are species recitations matching the core structures in claims 1 and 2, so they generally do not broaden coverage beyond the already specified structures.
References
(No external sources were used.)
More… ↓
⤷ Start Trial
|
